O
OPKO Health, Inc. (OPK)
NMS – Real vaqt narxi. Valyuta: USD
1.10
-0.02 (-1.79%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
1.10
-0.02 (-1.79%)
Yopilishda: May 12, 2026, 4:00 PM EDT
OPKO Health, Inc. AQSh, Irlandiya, Chili, Ispaniya, Isroil, Meksika va xalqaro miqyosda sog'liqni saqlash kompaniyasi sifatida faoliyat yuritadi. Kompaniya ikkita segmentda ishlaydi: Farmatsevtika va Diagnostika. Farmatsevtika segmenti klinik sinovlarning 1-bosqichida bir nechta turdagi qattiq o'smalarga qarshi to'rt spetsifik antitelani ishlab chiqmoqda; klinik sinovlarning 1-bosqichida gematologik o'smalar uchun ikkita antigenga qarshi to'rt spetsifik antitelani ishlab chiqmoqda; va bemorning o'z immunitet tizimini tiklash va qo'llab-quvvatlash uchun uch spetsifik immunitet modulyatorini ishlab chiqmoqda. Ushbu segment, shuningdek, Epstein Barr virusiga qarshi vaksina ishlab chiqish bilan shug'ullanadi; Rayaldee, prohormonni o'z ichiga olgan og'iz orqali yuboriladigan patentlangan uzaytirilgan-reliz mahsuloti; qon glyukozasini tartibga solish va tana vaznini kamaytirish uchun OPK-88006 og'iz va in'ektsion mahsuloti; o'sish gormoni etishmovchiligi bo'lgan bolalarni uzoq muddat davolash uchun ishlab chiqilgan rekombinant inson o'sish gormoni mahsuli NGENLA. Diagnostika segmenti BioReference brendi ostida kasalliklarni aniqlash, tashxislash, baholash, monitoring qilish va davolash, shuningdek, ezoterik testlar, molekulyar diagnostika, anatomik patologiya, genetika, ayollar salomatligi va tuzatuvchi sog'liqni saqlash kabi laboratoriya sinov xizmatlarini taklif etadi; va 4Kscore testi. OPKO Health, Inc. 2006 yilda tashkil etilgan va shtab-kvartirasi Mayami, Florida shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Akhtar Ashfaq FACP, FASN, M.D. | Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal |
| Dr. Charles W. Bishop Ph.D. | Chief Executive Officer of OPKO Renal |
| Dr. Elias Adam Zerhouni M.D. | President & Vice Chairman of the Board |
| Dr. Gary J. Nabel M.D., Ph.D. | Chief Innovation Officer & Director |
| Dr. Jane H. Hsiao M.B.A., Ph.D. | Vice Chairman of the Board & Chief Technical Officer |
| Dr. John R. Mascola M.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEFA14A | opk-20260429.htm |
| 2026-04-30 | DEF 14A | opk-20260430.htm |
| 2026-04-28 | 10-Q | opk-20260331.htm |
| 2026-03-19 | 8-K | opk-20260318.htm |
| 2026-02-26 | 8-K | opk-20260226.htm |
| 2026-02-26 | 10-K | opk-20251231.htm |
| 2025-10-29 | 8-K | opk-20251029.htm |
| 2025-10-29 | 10-Q | opk-20250930.htm |
| 2025-09-15 | 8-K | opk-20250915.htm |
| 2025-07-31 | 8-K | opk-20250731.htm |
| Chief Scientific Officer of ModeX |
| Dr. Phillip Frost M.D., Ph.D. | Chairman of the Board & CEO |
| Mr. Adam E. Logal | Senior VP, CFO, Chief Accounting Officer & Treasurer |
| Mr. Giovanni Abbadessa M.D., Ph.D. | Chief Medical Officer of ModeX |
| Mr. Steven D. Rubin Esq., J.D. | Executive VP of Administration & Director |